|
|||||
|
|
Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis |
|
| Authors: | Dyfrig A. Hughes Giovanna Culeddu Catrin O. Plumpton Eifiona Wood Andrew D. Dick Ashley P. Jones Andrew McKay Paula R. Williamson Sandrine Compeyrot Lacassagne Ben Hardwick Helen Hickey Patricia Woo Michael W. Beresford Athimalaipet V. Ramanan |
| Affiliation: | 1. Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, United Kingdom;2. Bristol Eye Hospital, Bristol, United Kingdom;3. Bristol Medical School, University of Bristol, Bristol, United Kingdom;4. Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom;5. UCL Institute of Ophthalmology and National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, United Kingdom;6. Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom;7. University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom |
| Abstract: | |
| Keywords: | CI confidence interval CR central range DMARD Disease-Modifying Anti-Rheumatic Drug HUI Health Utility Index ICER incremental cost-effectiveness ratio JIA juvenile idiopathic arthritis logMAR logarithm of the minimum angle of resolution NHS National Health Service QALY quality-adjusted life-year SYCAMORE Randomised controlled trial of the clinical effectiveness, SafetY and Cost effectiveness of Adalimumab in combination with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis |
| 本文献已被 ScienceDirect 等数据库收录！ | |